title: Immunotherapy with dendritic cells as a cancer treatment: perspectives and therapeutic potential.
abstract: The immune system, which is indispensible for controlling neoplasias, relies on its innate and acquired immunity components to mount an effective response against tumors. In this context, dendritic cells (DCs) are seen as the best antigen-presenting cells because of their capacity for cross-presentation, which can activate both T-helper and cytotoxic lymphocytes. Thus immunotherapy with DCs is considered promising, especially for early-stage cancers. This article provides a clarifying review of recent perspectives on the development of cancer immunotherapy, which has a wide potential for therapeutic applications, and of patents related to immunotherapy with DCs.
authors.affiliation: Oncology Research Institute (IPON)/ Discipline of Gynecology and Obstetrics, (UFTM), Avenida Getulio Guarita, sn, Uberaba (MG), CEP 38025-440, Bairro Abadia, Brazil. eddiemurta@mednet.com.br.
authors.forename: André A R
authors.initials: AA
authors.lastname: Aleixo
authors.forename: Márcia A
authors.initials: MA
authors.lastname: Michelin
authors.forename: Eddie F C
authors.initials: EF
authors.lastname: Murta
mesh_terms: D000938:Antigen-Presenting Cells / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008213:Lymphocyte Activation / Q000502:physiology; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D010330:Patents as Topic; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology
chemical_list: D000951:Antigens, Neoplasm